Suppression of Interferon-Mediated Antiviral Immunity by Hepatitis B Virus: An Overview of Research Progress

Scandinavian Journal of Immunology

Volumn 78, Issue 3, 2013, Pages 230-237

  Guo, P ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; BETA INTERFERON; CXCL9 CHEMOKINE; FAS LIGAND; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 18; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN KINASE; STAT1 PROTEIN;

ANTIGEN PRESENTING CELL; ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HEPATITIS B; HEPATITIS B VIRUS; INNATE IMMUNITY; INTERFERON PRODUCTION; KUPFFER CELL; LIVER CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VIRUS GENOME;

ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; SIGNAL TRANSDUCTION;

EID: 84883011854     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12086     Document Type: Review

References (101)

1. Seki S, Habu Y, Kawamura T, et al. The liver as a crucial organ in the first line of host defense: the roles of Kupffer cells, natural killer (NK) cells and NK1.1 Ag+ T cells in T helper 1 immune responses. Immunol Rev 2000;174:35-46.
2. Kadowaki N, Liu YJ. Natural type I interferon-producing cells as a link between innate and adaptive immunity. Hum Immunol 2002;63:1126-32.
3. Chen Y, Wei H, Gao B, Hu Z, Zheng S, Tian Z. Activation and function of hepatic NK cells in hepatitis B infection: an underinvestigated innate immune response. J Viral Hepatitis 2005;12:38-45.
4. Baron JL, Gardiner L, Nishimura S, Shinkai K, Locksley R, Ganem D. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity 2002;16:583-94.
5. Boehme KW, Compton T. Innate sensing of viruses by toll-like receptors. J Virol 2004;78:7867-73.
6. Yu XL, Lv LP, Yan F, et al. Effect of hepatitis B virus attack on the expression of interferon-beta in hepatocytes. Bull Acad Mil Med Sci 2011;35:587-92.
7. Bonjardim CA, Ferreira PCP, Kroon EG. Interferons: signaling, antiviral and viral evasion. Immunol Lett 2009;122:1-11.
8. Chen J, Wang XM, Wu XJ, et al. Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B. Inflamm Res 2011;60:47-53.
9. Shi CC, Xie Q, Zhao GD, et al. PD-L1 expression in hepatocytes and the regulation by interferon-α and hepatitis B virus. Chin Hepatol 2010;15:23-5.
10. Kakimi K, Lane TE, Wieland S, et al. Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med 2001;194:1755-66.
11. Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV. Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J Immunol 2002;169:5188-95.
12. Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol 2002;76:10702-7.
13. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000;192:921-30.
14. Smith PL, Lombardi G, Foster GR. Type I interferons and the innate immune response-more than just antiviral cytokines. Mol Immunol 2005;42:869-77.
15. Touzot M, Soumelis V, Asselah T. A dive into the complexity of type I interferon antiviral functions. J Hepatol 2012;56:726-8.
16. Peltekian C, Gordien E, Garreau F, et al. Human MxA protein participates to the interferon-related inhibition of hepatitis B virus replication in female transgenic mice. J Hepatol 2005;43:965-72.
17. Chai Y, Huang H-L, Hu D-J, et al. IL-29 and IFN-α regulate the expression of MxA, 2′, 5′-OAS and PKR genes in association with the activation of Raf-MEK-ERK and PI3K-AKT signal pathways in HepG2.2.15 cells. Mol Biol Rep 2010;38:139-43.
18. Fensterl V, Sen GC. The ISG56/IFIT1 gene family. J Interferon Cytokine Res 2011;31:71-8.
19. Turelli P, Mangeat B, Jost S, Vianin S, Trono D. Inhibition of hepatitis B virus replication by APOBEC3G. Science 2004;303:1829.
20. Robek MD, Wieland SF, Chisari FV. Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J Virol 2002;76:3570-4.
21. Alsharifi M, Mullbacher A, Regner M. Interferon type I responses in primary and secondary infections. Immunol Cell Biol 2008;86:239-45.
22. Liang WF. Study on the anti-hepatitis B virus with Peg-IFNα-2a and IFNα-2a in vitro and in vivo [Dissertation]. Guangzhou: First Military Medical University, 2007.
23. Zeng WQ. Observation on the effect of Pegasys in combination with adefovir dipivoxil on hepatitis B patients. China Trop Med 2006;6:822-3.
24. Gough DJ, Levy DE, Johnstone RW, Clarke CJ. IFNγ signaling-Does it mean JAK-STAT? Cytokine Growth Factor Rev 2008;19:383-94.
25. Zhang XH, Wu GT, Zhou P. Clinical anti-HBV effect by famciclovir in combination with interferon-γ. Chin J Mod Appl Pharm 2005;22:262-4.
26. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006;1:23-61.
27. Chisari FV, Hepatitis B. virus transgenic mice: models of viral immunobiology and pathogenesis. Curr Top Microbiol Immunol 1996;206:149-73.
28. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 2004;101:6669-74.
29. Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev 2012;25:142-63.
30. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007;46:160-70.
31. Liaw YF. Impact of hepatitis B therapy on the long-term outcome of liver disease. Liver Int 2011;31(Suppl. 1):117-21.
32. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009;49:S174-84.
33. Tillmann HL. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol 2007;13:125-40.
34. Zoulim F. Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance? Antivir Chem Chemother 2004;15:299-305.
35. Fournier C, Zoulim F. Antiviral therapy of chronic hepatitis B: prevention of drug resistance. Clin Liver Dis 2007;11:869-92. ix.
36. Genin P, Lin R, Hiscott J, Civas A. Differential regulation of human interferon A gene expression by interferon regulatory factors 3 and 7. Mol Cell Biol 2009;29:3435-50.
37. Lei CQ, Zhong B, Zhang Y, Zhang J, Wang S, Shu HB. Glycogen synthase kinase 3beta regulates IRF3 transcription factor-mediated antiviral response via activation of the kinase TBK1. Immunity 2010;33:878-89.
38. Levy DE, Marie I, Smith E, Prakash A. Enhancement and diversification of IFN induction by IRF-7-mediated positive feedback. J Interferon Cytokine Res 2002;22:87-93.
39. Heydtmann M. Macrophages in hepatitis B and hepatitis C virus infections. J Virol 2009;83:2796-802.
40. Cui GY, Diao HY. Recognition of HBV antigens and HBV DNA by dendritic cells. Hepatobiliary Pancreat Dis Int 2010;9:584-92.
41. Qian ZP, Li N, Zheng ZP, et al. HBV inhibits the expressions of TLR3, Mda-5 and RIG-I in macrophage cells. Chin Hepatol 2010;15:425-8.
42. An BY, Xie Q, Wang H, et al. Expression and significance of interferon regulatory factor 3 of peripheral blood dendritic cells in HBV-infected patients. World Chin J Digestol 2008;16:1873-9.
43. Wieland SF, Vega RG, Muller R, et al. Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol 2003;77:1227-36.
44. Hu J. Induction of cytokine on hepatocytes by cytokine inducer PPD, polyI:C and PHA [Dissertation]. Chongqin: Chongqin Medical University, 2008.
45. Han Q, Zhang C, Zhang J, Tian Z. Reversal of hepatitis B virus-induced immune tolerance by an immunostimulatory 3p-HBx-siRNAs in a retinoic acid inducible gene I-dependent manner. Hepatology 2011;54:1179-89.
46. Wu YY. The regulation of HBcAg and TBKl on production of IFN-β induced by dsRNA in hepatocytes [Dissertation]. Hangzhou: Zhejiang University, 2008.
47. Wu J, Meng Z, Jiang M, et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009;49:1132-40.
48. Yu S, Chen J, Wu M, Chen H, Kato N, Yuan Z. Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol 2010;91:2080-90.
49. Wei C, Ni C, Song T, et al. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol 2010;185:1158-68.
50. Kumar M, Jung SY, Hodgson AJ, Madden CR, Qin J, Slagle BL. Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon. J Virol 2011;85:987-95.
51. Wang X, Li Y, Mao A, Li C, Tien P. Hepatitis B virus X protein suppresses virus-triggered IRF3 activation and IFN-beta induction by disrupting the VISA-associated complex. Cell Mol Immunol 2010;7:341-8.
52. Jiang J, Tang H. Mechanism of inhibiting type I interferon induction by hepatitis B virus X protein. Protein Cell 2010;1:1106-17.
53. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007;282:20059-63.
54. Schoggins JW, Rice CM. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol 2011;1:519-25.
55. Liu M, Hao Y, Ding H, Yang D, Lu M. Interleukin-10 is expressed in HepG2.2.15 cells and regulated by STAT1 pathway. J Huazhong Univ Sci Technolog Med Sci 2011;31:625-31.
56. Fan HB, Guo YB, Wang BJ, et al. Expression of IFN-α/β receptor in the PBMCs and liver of patients with hepatitis B and its clinical significance. J South Med Univ 2008;28:979-81.
57. Ren SP Effect of hepatitis B virus on expression of type I interferon receptor [Dissertation]. Hangzhou: Zhejiang University, 2000.
58. Chung Y-H. Hepatitis B virus X protein inhibits extracellular IFN-α-mediated signal transduction by downregulation of type I IFN receptor. Int J Mol Med 2012;29:581-6.
59. Guan SH, Lu M, Grunewald P, Roggendorf M, Gerken G, Schlaak JF. Interferon-alpha response in chronic hepatitis B-transfected HepG2.2.15 cells is partially restored by lamivudine treatment. World J Gastroenterol 2007;13:228-35.
60. Xiong W. Interferon-inducible MyD88 protein inhibits hepatitis B virus replication [D] [Dissertation]. Shanghai: Fudan University, 2004.
61. Wang X. Interaction of hepatitis B virus with interferon-α inducible cellular proteins [Dissertation]. Shanghai: Fudan University, 2004.
62. Wu M. Mechanisms of inhibiting interferon-inducible MyD88 hepatitis B virus [Dissertation]. Shanghai: Fudan University, 2007.
63. Lin SS. Molecular mechanisms of the inhibition of HBV gene replication by MyD88 protein [Dissertation]. Shanghai: Fudan University, 2007.
64. Wu M, Xu Y, Lin S, Zhang X, Xiang L, Yuan Z. Hepatitis B virus polymerase inhibits the interferon-inducible MyD88 promoter by blocking nuclear translocation of Stat1. J Gen Virol 2007;88:3260-9.
65. Yu SY. Preliminary study on mechanisms of interfering with IFN-α induced signaling pathway by hepatitis B virus [Dissertation]. Shanghai: Fudan University, 2005.
66. Wang L. The anti-IFN-α effects of the Tp associated protein of hepatitis B virus [Dissertation]. Fuzhou: Fujian Medical University, 2009.
67. Guan SH, Yang K, Pan Y. Study of the effect of hepatitis B virus on interferon-induced antiviral proteins expression. Acta Universitatis Medicinalis Anhui 2011;46:324-7.
68. Guan SH, Yang K, Lu MJ, Lu YP, Yang DL. The influence of HBV and its antigens on the expressions of JAK-STAT signal transduction pathway molecules and antiviral proteins of IFN alpha. Chin J Hepatol 2011;19:440-4.
69. Siebler J, Protzer U, Wirtz S, et al. Overexpression of STAT-1 by adenoviral gene transfer does not inhibit hepatitis B virus replication. Eur J Gastroenterol Hepatol 2006;18:167-74.
70. Zhang Q, Wang Y, Wei L, et al. Role of ISGF3 in modulating the anti-hepatitis B virus activity of interferon-alpha in vitro. J Gastroenterol Hepatol 2008;23:1747-61.
71. Christen V, Treves S, Duong FH, Heim MH. Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. Hepatology 2007;46:558-65.
72. Li J, Chen F, Zheng M, et al. Inhibition of STAT1 methylation is involved in the resistance of hepatitis B virus to Interferon alpha. Antiviral Res 2010;85:463-9.
73. Cheng ZL, Guan SH, Yang K, Pan Y. Effect of SOCS1 on the antiviral replication of interferon-α. Acta Universitatis Medicinalis Anhui 2011;46:228-30.
74. Su C, Hou Z, Zhang C, Tian Z, Zhang J. Ectopic expression of microRNA-155 enhances innate antiviral immunity against HBV infection in human hepatoma cells. Virol J 2011;8:354.
75. Fish EN, Uddin S, Korkmaz M, Majchrzak B, Druker BJ, Platanias LC. Activation of a CrkL-stat5 signaling complex by type I interferons. J Biol Chem 1999;274:571-3.
76. Uddin S, Lekmine F, Sharma N, et al. The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J Biol Chem 2000;275:27634-40.
77. Uddin S, Majchrzak B, Woodson J, et al. Activation of the p38 mitogen-activated protein kinase by type I interferons. J Biol Chem 1999;274:30127-31.
78. Uddin S, Sassano A, Deb DK, et al. Protein kinase C-delta (PKC-delta) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem 2002;277:14408-16.
79. Haller O, Kochs G. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res 2011;31:79-87.
80. Li N, Zhang L, Chen L, et al. MxA inhibits hepatitis B virus replication by interaction with core protein HBcAg. Hepatology 2012;56:803-11.
81. Gordien E, Rosmorduc O, Peltekian C, Garreau F, Brechot C, Kremsdorf D. Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein. J Virol 2001;75:2684-91.
82. Yang K. Primary research of the antagonistic action of HBV and its antigen components on the antiviral activity of interferon-α [Dissertation]. Hefei: Anhui Medical University, 2010.
83. Rosmorduc O, Petit MA, Pol S, et al. In vivo and in vitro expression of defective hepatitis B virus particles generated by spliced hepatitis B virus RNA. Hepatology 1995;22:10-9.
84. Fernandez M, Quiroga JA, Carreno V. Hepatitis B virus downregulates the human interferon-inducible MxA promoter through direct interaction of precore/core proteins. J Gen Virol 2003;84:2073-82.
85. Rosmorduc O, Sirma H, Soussan P, et al. Inhibition of interferon-inducible MxA protein expression by hepatitis B virus capsid protein. J Gen Virol 1999;80(Pt 5):1253-62.
86. Yang YL, Reis LF, Pavlovic J, et al. Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO J 1995;15:14.
87. Park I-H, Baek K-W, Cho E-Y, Ahn B-Y. PKR-dependent mechanisms of interferon-α for inhibiting hepatitis B virus replication. Mol Cells 2011;32:167-72.
88. Chen GG, Lai PB, Ho RL, et al. Reduction of double-stranded RNA-activated protein kinase in hepatocellular carcinoma associated with hepatitis B virus. J Med Virol 2004;73:187-94.
89. Han Q, Zhang C, Zhang J, Tian Z. Involvement of activation of PKR in HBx-siRNA-mediated innate immune effects on HBV inhibition. PLoS ONE 2011;6:e27931.
90. Kim BK, Revill PA, Ahn SH. HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther 2011;16:1169-86.
91. Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005;54:1009-13.
92. Ma JC, Wang LW, Li XJ, Liao YF, Hu XY, Gong ZJ. Relationship between HBV genotypes and anti-viral therapeutic efficacy of interferon-alpha. Hepatobiliary Pancreat Dis Int 2007;6:166-71.
93. Chinese Society of Hepatology and Chinese Society of Infectious Diseases CMA. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Chin J Hepatol 2011;19:13-24.
94. Shao G. Experiment study on the mutant mechanism of HBV C gene with the treatment of IFN in vitro and application of HepG2.2.15 cell [Dissertation]. Guangzhou: Sun Yat-sen University, 2006.
95. Liu CJ, Kao JH. Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir Ther 2008;13:613-24.
96. Wang WF, Zhou XD. An in vitro study on the mutant of HBV treated with interferon. Chin J Hepatol 2005;13:793-4.
97. Liu Y, Ni X. Relationship between the replication of hepatitis B virus and HBV precoremutation in chronic hepatitis B patients. Hebei Med J 2007;29:1056-8.
98. Chotiyaputta W, Lok AS. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 2009;6:453-62.
99. Mason A, Wick M, White H, Perrillo R. Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection. Hepatology 1993;18:781-9.
100. Schildgen O. Host factors may influence response to antiviral therapy in chronic hepatitis B virus infections. Med Hypotheses 2011;76:417-20.
101. Kong XF. Study on the correlation between interferon signal transduction systems and hepatitis B [Dissertation]. Shanghai: Shanghai Second Medical University, 2004.